---
title: "TEVA: TEV ‘408 significantly prevented gluten-induced intestinal damage in celiac disease Phase 2a study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297776333.md"
description: "A Phase 2a study of TEV ‘408 in celiac disease met its primary endpoint, showing significant prevention of gluten-induced intestinal damage and favorable effects on inflammation and symptoms. TEV ‘408 was well-tolerated, supporting its potential as a pipeline-in-a-product.Original document: Teva Pharmaceutical Industries Limited [TEVA] Press release — Sep. 2 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-02T11:16:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297776333.md)
  - [en](https://longbridge.com/en/news/297776333.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297776333.md)
generator: "portal-rs"
---

# TEVA: TEV ‘408 significantly prevented gluten-induced intestinal damage in celiac disease Phase 2a study

A Phase 2a study of TEV ‘408 in celiac disease met its primary endpoint, showing significant prevention of gluten-induced intestinal damage and favorable effects on inflammation and symptoms. TEV ‘408 was well-tolerated, supporting its potential as a pipeline-in-a-product.

Original document: Teva Pharmaceutical Industries Limited \[TEVA\] Press release — Sep. 2 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [TEVA.US](https://longbridge.com/en/quote/TEVA.US.md)

## Related News & Research

- [Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study](https://longbridge.com/en/news/297800772.md)
- [Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes | TEVA Stock News](https://longbridge.com/en/news/298575790.md)
- [Compass Financial Management LLC Purchases New Stake in Teva Pharmaceutical Industries Ltd. $TEVA](https://longbridge.com/en/news/298183025.md)
- [Teva Announces Launch of Offering of Senior Notes | TEVA Stock News](https://longbridge.com/en/news/298183684.md)
- [Teva prices $4.9bn equivalent senior notes, issues five tranches maturing 2032–2037](https://longbridge.com/en/news/298765758.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**